Navigation Links
AHIP Statement on New CMS Guidelines for Agent and Broker Commissions in Medicare Advantage
Date:11/10/2008

WASHINGTON, Nov. 10 /PRNewswire-USNewswire/ -- Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), today issued the following statement on new guidelines announced by CMS on agent and broker compensation for Medicare Advantage plans:

"We commend CMS for taking this important step to provide guidelines for agent and broker commissions. It is vital that seniors receive the information they need during open enrollment, that brokers receive reasonable compensation for the valuable services they provide, and that there are clear standards in place.

Establishing guidelines in this area is an important regulatory responsibility. We are committed to working with CMS and key stakeholders to protect beneficiaries."

America's Health Insurance Plans - Providing Health Benefits to More Than 200 Million Americans


'/>"/>
SOURCE America's Health Insurance Plans
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. REVISED AND UPDATED: Firearms Industry Statement on Results of CDC Blood Lead Levels in Hunters Study
2. NCPA Statement on Florida Study About Prescription Drug Prices in Underserved Areas
3. Firearms Industry Statement on Results of CDC Blood Lead Levels in Hunters Study
4. NCPA Statement on November 4th Election Results
5. Statement by Californians For SAFE Food Regarding Proposition 2 Results
6. Statement on Courage Campaign Ad from NO on Prop 8
7. Council for Quality Respiratory Care Statement
8. NO on Prop 8 Campaign Releases Statement by 300 California Pediatricians
9. Phyhealth Issues 2008 Third Quarter Financial Statements
10. Grocery Manufacturers Association Statement Regarding FDA Science Board Advisory Report on Bisphenol A (BPA)
11. Grocery Manufacturers Association Statement Regarding FDA Science Board Advisory Report on Bisphenol A (BPA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: